Optimizing the outcomes of pancreatic cancer surgery
Optimizing the outcomes of pancreatic cancer surgery, Published online: 19 October 2018; doi:10.1038/s41571-018-0112-1Successful surgical resection offers patients with pancreatic cancer the best chance of survival. However, many patients do not have surgically resectable disease. In this Review, the authors describe recent improvements in pancreatic cancer surgery, which have increased survival and also enabled more patients to undergo surgery. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - October 19, 2018 Category: Cancer & Oncology Authors: Oliver Strobel John Neoptolemos Dirk J äger Markus W. B üchler Source Type: research

NTRK fusion-positive cancers and TRK inhibitor therapy
NTRK fusion-positive cancers and TRK inhibitor therapy, Published online: 17 October 2018; doi:10.1038/s41571-018-0113-0TRK fusion proteins are pathognomonic is certain rare tumour types and present in a small subset of diverse cancer types, including some common cancers; TRK inhibitors have promising efficacy in the treatment of these cancers, in a histology-agnostic manner. In this Review, the biology of TRK signalling and TRK fusions, strategies to target these drivers, the unique safety profile of TRK inhibitors and mechanisms of and strategies to overcome acquired resistance to these agents are discussed. (Source: Nat...
Source: Nature Clinical Practice Oncology - October 17, 2018 Category: Cancer & Oncology Authors: Emiliano Cocco Maurizio Scaltriti Alexander Drilon Source Type: research

The promise of ESCAT: a new system for evaluating cancer drug–target pairs
The promise of ESCAT: a new system for evaluating cancer drug–target pairsThe promise of ESCAT: a new system for evaluating cancer drug–target pairs, Published online: 13 October 2018; doi:10.1038/s41571-018-0110-3The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) will be useful as a common language to harmonize discussions in precision oncology and could also guide policy and reimbursement decisions, but it is far from perfect. Herein, we highlight how ESCAT can be further improved to increase its utility in clinical and policy decisions. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - October 13, 2018 Category: Cancer & Oncology Authors: Bishal Gyawali Aaron S. Kesselheim Source Type: research

A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer
A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer, Published online: 05 October 2018; doi:10.1038/s41571-018-0108-xA minority of patients with gastroesophageal adenocarcinoma derive benefit from immune-checkpoint inhibition (ICI). In a large-cohort phase III study, the nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) arm (which was based on promising preliminary data from CheckMate 032) was closed owing to unacceptably high levels of mortality and morbidity. Our quest for better biomarkers than programmed cell death 1 ligand 1 (PD-L1) and safer dual ICI strategies must continue. (Sou...
Source: Nature Clinical Practice Oncology - October 5, 2018 Category: Cancer & Oncology Authors: Kazuto Harada Ahmed A. F. Abdelhakeem Jaffer A. Ajani Source Type: research

The biology and treatment of Merkel cell carcinoma: current understanding and research priorities
The biology and treatment of Merkel cell carcinoma: current understanding and research priorities, Published online: 04 October 2018; doi:10.1038/s41571-018-0103-2Merkel cell carcinoma (MCC) is a rare and aggressive form of nonmelanoma skin cancer. The availability of immune checkpoint inhibition has improved the outcomes of a subset of patients with MCC, although many unmet needs continue to exist. In this Consensus Statement, the authors summarize developments in our understanding of MCC while also providing consensus recommendations for future research. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - October 4, 2018 Category: Cancer & Oncology Authors: Paul W. Harms Kelly L. Harms Patrick S. Moore James A. DeCaprio Paul Nghiem Michael K. K. Wong Isaac Brownell Source Type: research

From WCLC 2018
From WCLC 2018, Published online: 02 October 2018; doi:10.1038/s41571-018-0109-9From WCLC 2018 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - October 2, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Therapeutic strategies to target RAS-mutant cancers
Therapeutic strategies to target RAS-mutant cancers, Published online: 01 October 2018; doi:10.1038/s41571-018-0105-0Effective therapeutic strategies to target RAS-mutant cancers have proved elusive, but in the past few years, several promising strategies have been tested in clinical trials. The authors describe historical and ongoing therapeutic approaches based on the direct or indirect targeting of RAS. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - October 1, 2018 Category: Cancer & Oncology Authors: Meagan B. Ryan Ryan B. Corcoran Source Type: research

Accelerating anticancer drug development — opportunities and trade-offs
Accelerating anticancer drug development — opportunities and trade-offsAccelerating anticancer drug development — opportunities and trade-offs, Published online: 01 October 2018; doi:10.1038/s41571-018-0102-3With the expansion of the precision medicine paradigm, seamless trial approaches to drug development hold great promise for accelerating the accessibility of novel therapeutic agents but are also accompanied by important trade-offs. The authors describe several opportunities to improve the efficiency of drug development in oncology, as well as new mechanisms to obtain information about anticancer therapies ...
Source: Nature Clinical Practice Oncology - October 1, 2018 Category: Cancer & Oncology Authors: Sharyl J. Nass Mace L. Rothenberg Rebecca Pentz Hedvig Hricak Amy Abernethy Kenneth Anderson Amanda Wagner Gee R. Donald Harvey Steven Piantadosi Monica M. Bertagnolli Deborah Schrag Richard L. Schilsky Source Type: research

AI to assess images
AI to assess images, Published online: 28 September 2018; doi:10.1038/s41571-018-0107-yAI to assess images (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 28, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Insights into the risk of fatal AEs with ICIs
Insights into the risk of fatal AEs with ICIs, Published online: 27 September 2018; doi:10.1038/s41571-018-0104-1Insights into the risk of fatal AEs with ICIs (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 27, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

The murky world of disclosures
The murky world of disclosures, Published online: 27 September 2018; doi:10.1038/s41571-018-0106-zThe murky world of disclosures (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 27, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Why patients receive treatments that are minimally effective?
Why patients receive treatments that are minimally effective?, Published online: 24 September 2018; doi:10.1038/s41571-018-0101-4The value of medical treatments is an issue that has been actively debated in recent years and is not unique to oncology. In this Comment, we discuss why we pursue treatments which might have limited benefit from the point of view of three parties: the patient, the physician, and the pharmaceutical industry. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 24, 2018 Category: Cancer & Oncology Authors: Christopher M. Booth Allan S. Detsky Source Type: research

Let’s address burnout in oncologists and reimagine the way we work
Let’s address burnout in oncologists and reimagine the way we workLet’s address burnout in oncologists and reimagine the way we work, Published online: 21 September 2018; doi:10.1038/s41571-018-0097-9Burnout is a substantial issue associated with the medical profession, with oncology being no exception. Increasing focus is being placed on implementing solutions to address physician burnout, and successful interventions have encompassed the following themes: the presence of an organizational mandate, data-driven and grassroots quality improvements, and a focus on systems change. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 21, 2018 Category: Cancer & Oncology Authors: Krithika Murali Susana Banerjee Source Type: research

Chemoprevention of Barrett’s oesophagus: a step closer with PPIs and aspirin
Chemoprevention of Barrett’s oesophagus: a step closer with PPIs and aspirinChemoprevention of Barrett’s oesophagus: a step closer with PPIs and aspirin, Published online: 20 September 2018; doi:10.1038/s41571-018-0096-xChemoprevention for patients with Barrett’s oesophagus remains a controversial topic. Results of the first randomized trial of chemoprevention using a proton pump inhibitor with or without aspirin were recently reported. We highlight strengths and weaknesses in the design of the trial and discuss the clinical implications of the findings. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 20, 2018 Category: Cancer & Oncology Authors: Nisreen S. Husain Hashem B. El-Serag Source Type: research

Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
Roles of the RANKL–RANK axis in antitumour immunity — implications for therapyRoles of the RANKL–RANK axis in antitumour immunity — implications for therapy, Published online: 19 September 2018; doi:10.1038/s41571-018-0095-yIntriguing evidence suggests that expression of RANK or RANKL by various cells of the tumour microenvironment modulates the anticancer immune response. Herein, the authors review this evidence, discuss the current preclinical and clinical data supporting a potential of RANKL inhibition to improve anticancer immunotherapy and describe hypothetical immune-related mechanisms of acti...
Source: Nature Clinical Practice Oncology - September 19, 2018 Category: Cancer & Oncology Authors: Elizabeth Ahern Mark J. Smyth William C. Dougall Michele W. L. Teng Source Type: research

PD-1 mRNA predicts response to therapy
PD-1 mRNA predicts response to therapy, Published online: 14 September 2018; doi:10.1038/s41571-018-0100-5PD-1 mRNA predicts response to therapy (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 14, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Immunogenomic features of mCRPC revealed
Immunogenomic features of mCRPC revealed, Published online: 14 September 2018; doi:10.1038/s41571-018-0098-8Immunogenomic features of mCRPC revealed (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 14, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Erlotinib effective in the neoadjuvant setting
Erlotinib effective in the neoadjuvant setting, Published online: 14 September 2018; doi:10.1038/s41571-018-0099-7Erlotinib effective in the neoadjuvant setting (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 14, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Precision risk-based screening might maximize benefit and minimize harm
Precision risk-based screening might maximize benefit and minimize harm, Published online: 14 September 2018; doi:10.1038/s41571-018-0093-0Population-based mammographic screening is widely accepted as an intervention to reduce overall mortality from breast cancer, but at the cost of morbidity due to false positives and substantial overdiagnosis and overtreatment of ultra-low-risk disease, as well as personal and health-economic burdens. Recent data from a modelling study strengthen the rationale for personalized, risk-based screening approaches, now being tested in multiple clinical trials. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 14, 2018 Category: Cancer & Oncology Authors: Laura J. Esserman Andrea Z. LaCroix Source Type: research

Progress in adjuvant systemic therapy for breast cancer
Progress in adjuvant systemic therapy for breast cancer, Published online: 11 September 2018; doi:10.1038/s41571-018-0089-9Improvements in the management of patients with early stage breast cancer have been achieved through intense therapeutic escalation but also with de-escalation of systemic therapies. The authors of this Review summarize key trials using both approaches and highlight the need to use therapeutic escalation for patients who would benefit from that approach and de-escalation for patients with a favourable prognosis. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 11, 2018 Category: Cancer & Oncology Authors: Noam F. Pond é Dimitrios Zardavas Martine Piccart Source Type: research

What’s new under the Sun for ICIs?
What’s new under the Sun for ICIs?What’s new under the Sun for ICIs?, Published online: 07 September 2018; doi:10.1038/s41571-018-0094-zWhat’s new under the Sun for ICIs? (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 7, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission
Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remissionEliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission, Published online: 04 September 2018; doi:10.1038/s41571-018-0087-yThe approval of blinatumomab based on achievement of undetectable minimal residual disease (MRD) in patients with B cell acute lymphoblastic leukaemia in complete remission is the first of its kind and raises important considerations. This drug might improve outcomes in this setting, although considerable evidence is needed to validate the performance of MRD as a surrogate end point and conf...
Source: Nature Clinical Practice Oncology - September 4, 2018 Category: Cancer & Oncology Authors: Talal Hilal Vinay Prasad Source Type: research

ctDNA predicts outcomes in DLBCL
ctDNA predicts outcomes in DLBCL, Published online: 03 September 2018; doi:10.1038/s41571-018-0091-2ctDNA predicts outcomes in DLBCL (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 3, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Mesothelioma risk genes revealed
Mesothelioma risk genes revealed, Published online: 03 September 2018; doi:10.1038/s41571-018-0092-1Mesothelioma risk genes revealed (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 3, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

EMBRACing a new PARP inhibitor?
EMBRACing a new PARP inhibitor?, Published online: 03 September 2018; doi:10.1038/s41571-018-0090-3EMBRACing a new PARP inhibitor? (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 3, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Signatures IMPRES and might turn the TIDE in predicting responses
Signatures IMPRES and might turn the TIDE in predicting responses, Published online: 31 August 2018; doi:10.1038/s41571-018-0088-xSignatures IMPRES and might turn the TIDE in predicting responses (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - August 31, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Alternative splicing in prostate cancer
Alternative splicing in prostate cancer, Published online: 22 August 2018; doi:10.1038/s41571-018-0085-0Androgen receptor (AR) splice variants (AR-Vs) are truncated isoforms of the AR, of which a subset remain constitutively active in the absence of circulating androgens. AR-Vs have been proposed to contribute to therapeutic resistance. The authors of this Review outline the current understanding of the role of the spliceosome in prostate cancer progression and explore the therapeutic utility of manipulating alternative splicing. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - August 22, 2018 Category: Cancer & Oncology Authors: Alec Paschalis Adam Sharp Jonathan C. Welti Antje Neeb Ganesh V. Raj Jun Luo Stephen R. Plymate Johann. S. de Bono Source Type: research

Economic sustainability of immune-checkpoint inhibitors: the looming threat
Economic sustainability of immune-checkpoint inhibitors: the looming threat, Published online: 20 August 2018; doi:10.1038/s41571-018-0086-zImmune-checkpoint inhibitors (ICIs) are transforming oncology, but the mounting costs of cancer care necessitate concerns regarding economic sustainability. Here, several strategies that clinicians could use to exercise economically prudent administration of ICIs are discussed. These include better appraisal of the cost-effectiveness literature, judicious patient selection, separating statistical from clinical significance, and careful patient counselling. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - August 20, 2018 Category: Cancer & Oncology Authors: Vivek Verma Source Type: research

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?, Published online: 14 August 2018; doi:10.1038/s41571-018-0081-4The clinical management of patients with non-small-cell lung carcinoma has greatly evolved owing to the development of tyrosine-kinase inhibitors (TKIs) targeted against the driver mutations of this disease. The authors of this Review describe the existing evidence on the sequential administration of TKIs and the use of next-generation TKIs upfront. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - August 14, 2018 Category: Cancer & Oncology Authors: Gonzalo Recondo Francesco Facchinetti Ken A. Olaussen Benjamin Besse Luc Friboulet Source Type: research

Economic comments on proposal for a novel cancer drug pricing model
Economic comments on proposal for a novel cancer drug pricing model, Published online: 13 August 2018; doi:10.1038/s41571-018-0083-2Economic comments on proposal for a novel cancer drug pricing model (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - August 13, 2018 Category: Cancer & Oncology Authors: Mark J. C. Nuijten Jan Vis Source Type: research

Reply to ‘Economic comments on proposal for a novel cancer drug pricing model’
Reply to ‘Economic comments on proposal for a novel cancer drug pricing model’Reply to ‘Economic comments on proposal for a novel cancer drug pricing model’, Published online: 13 August 2018; doi:10.1038/s41571-018-0084-1Reply to ‘Economic comments on proposal for a novel cancer drug pricing model’ (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - August 13, 2018 Category: Cancer & Oncology Authors: Carin A. Uyl-de Groot Bob L öwenberg Source Type: research

MHC expression predicts response
MHC expression predicts response, Published online: 07 August 2018; doi:10.1038/s41571-018-0082-3MHC expression predicts response (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - August 7, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy, Published online: 06 August 2018; doi:10.1038/s41571-018-0075-2Chimeric antigen receptor (CAR) T cell therapies have impressive activity in the treatment of cancer but are associated with potentially fatal toxicities. In light of the approval of CAR T cell therapy for paediatric patients, a panel of experts from the Hematopoietic Stem Cell Transplantation (HSCT) Subgroup of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network, the CAR T Cell Therapy-Associated Toxicity (CARTOX) Program at The University of...
Source: Nature Clinical Practice Oncology - August 6, 2018 Category: Cancer & Oncology Authors: Kris M. Mahadeo Sajad J. Khazal Hisham Abdel-Azim Julie C. Fitzgerald Agne Taraseviciute Catherine M. Bollard Priti Tewari Christine Duncan Chani Traube David McCall Marie E. Steiner Ira M. Cheifetz Leslie E. Lehmann Rodrigo Mejia John M. Slopis Rajinder Source Type: research

Benefit of nanomedicine confirmed in sAML
Benefit of nanomedicine confirmed in sAML, Published online: 31 July 2018; doi:10.1038/s41571-018-0080-5Benefit of nanomedicine confirmed in sAML (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 31, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Molecular therapies and precision medicine for hepatocellular carcinoma
Molecular therapies and precision medicine for hepatocellular carcinoma, Published online: 30 July 2018; doi:10.1038/s41571-018-0073-4Molecular profiling studies are providing novel insights into the biology of hepatocellular carcinoma, although these remain to be translated into novel effective therapies. Nevertheless, therapeutic advances have been made in the past few years, and further advancements are expected in the near future, including biomarker-driven treatments and immunotherapies, as discussed in this Review. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 30, 2018 Category: Cancer & Oncology Authors: Josep M. Llovet Robert Montal Daniela Sia Richard S. Finn Source Type: research

Immunotherapy-responsive gastric cancers identified
Immunotherapy-responsive gastric cancers identified, Published online: 30 July 2018; doi:10.1038/s41571-018-0079-yImmunotherapy-responsive gastric cancers identified (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 30, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Viruses in cancer therapy — from benchwarmers to quarterbacks
Viruses in cancer therapy — from benchwarmers to quarterbacksViruses in cancer therapy — from benchwarmers to quarterbacks, Published online: 29 July 2018; doi:10.1038/s41571-018-0077-0A recent clinical trial of a virotherapy approach, consisting of an engineered poliovirus, has provided evidence of apparently durable responses in patients with recurrent glioblastoma. The results of this trial and others indicate that virotherapy might be an effective tool in anticancer immunotherapy. Yet, caution must be exercised until appropriately powered randomized clinical trials truly show efficacy. (Source: Nature Clini...
Source: Nature Clinical Practice Oncology - July 29, 2018 Category: Cancer & Oncology Authors: Pierpaolo Peruzzi E. Antonio Chiocca Source Type: research

Early prediction of AML risk
Early prediction of AML risk, Published online: 26 July 2018; doi:10.1038/s41571-018-0078-zEarly prediction of AML risk (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 26, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy
Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy, Published online: 26 July 2018; doi:10.1038/s41571-018-0074-3The majority of patients receiving immunotherapy do not respond to treatment but might still have adverse events. Furthermore, some patients with an initial response will develop acquired resistance to treatment. In this Review, the authors describe the role of circulating tumour DNA in the management of patients receiving immunotherapy. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 26, 2018 Category: Cancer & Oncology Authors: Luc Cabel Charlotte Proudhon Emanuela Romano Nicolas Girard Olivier Lantz Marc-Henri Stern Jean-Yves Pierga Fran çois-Clément Bidard Source Type: research

Uncovering the clonal basis of response and resistance to IDH2 inhibition in AML
Uncovering the clonal basis of response and resistance to IDH2 inhibition in AML, Published online: 25 July 2018; doi:10.1038/s41571-018-0076-1Uncovering the clonal basis of response and resistance to IDH2 inhibition in AML (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 25, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Infant medulloblastoma — learning new lessons from old strata
Infant medulloblastoma — learning new lessons from old strataInfant medulloblastoma — learning new lessons from old strata, Published online: 20 July 2018; doi:10.1038/s41571-018-0071-6Comprehensive molecular characterization of infant medulloblastoma has uncovered the high degree of heterogeneity of this disease. Recent results from the SJYC07 study elegantly reveal that risk stratification can be improved if DNA methylation profiling data are incorporated into clinicopathological criteria. Importantly, the delineation of disease subgroups potentially has major clinical implications. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 20, 2018 Category: Cancer & Oncology Authors: Marc Remke Vijay Ramaswamy Source Type: research

AR-V7 detection guides treatment
AR-V7 detection guides treatment, Published online: 17 July 2018; doi:10.1038/s41571-018-0072-5AR-V7 detection guides treatment (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 17, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Frontline immunotherapy for NSCLC: alone or not alone?
Frontline immunotherapy for NSCLC: alone or not alone?, Published online: 11 July 2018; doi:10.1038/s41571-018-0070-7Platinum-based chemotherapy has long been the mainstay first-line therapy for patients with non-small-cell lung cancer without a targetable driver mutation, but has limited effectiveness. Immunotherapy is drastically changing the treatment landscape for this group and improving survival outcomes, with focus turning to frontline immunotherapy combinations. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 11, 2018 Category: Cancer & Oncology Authors: Cesare Gridelli Francesca Casaluce Source Type: research

Sequencing cells of the immune TME
Sequencing cells of the immune TME, Published online: 09 July 2018; doi:10.1038/s41571-018-0069-0Sequencing cells of the immune TME (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 9, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Redefining KRAS activation
Redefining KRAS activation, Published online: 09 July 2018; doi:10.1038/s41571-018-0068-1Redefining KRAS activation (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 9, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Sodium thiosulfate halves the risk of cisplatin-induced hearing loss
Sodium thiosulfate halves the risk of cisplatin-induced hearing loss, Published online: 06 July 2018; doi:10.1038/s41571-018-0067-2Sodium thiosulfate halves the risk of cisplatin-induced hearing loss (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 6, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Reinforcing the social compromise of accelerated approval
Reinforcing the social compromise of accelerated approval, Published online: 03 July 2018; doi:10.1038/s41571-018-0066-3Accelerated approval enables investigational drugs to reach the US market on the basis of their demonstrated effects in unvalidated surrogate measures, only reasonably likely to predict clinical response. To fulfil the social compromise, regulators should ensure that confirmatory trials testing clinically meaningful end points are already underway at the time of approval. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 3, 2018 Category: Cancer & Oncology Authors: Bishal Gyawali Aaron S. Kesselheim Source Type: research

Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection
Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detectionEarly stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection, Published online: 03 July 2018; doi:10.1038/s41571-018-0058-3Liquid biopsy approaches hold great promise in early cancer diagnosis or minimal residual disease monitoring for cancer recurrence. Herein, the authors evaluate contemporary next-generation sequencing approaches to circulating tumour DNA detection in these contexts, with a focus on studies in patients with non-small-cell lung cancer. They discuss the feasibility of introducing the...
Source: Nature Clinical Practice Oncology - July 3, 2018 Category: Cancer & Oncology Authors: Christopher Abbosh Nicolai J. Birkbak Charles Swanton Source Type: research

Cytoreductive nephrectomy in metastatic renal cancer — less is more
Cytoreductive nephrectomy in metastatic renal cancer — less is moreCytoreductive nephrectomy in metastatic renal cancer — less is more, Published online: 02 July 2018; doi:10.1038/s41571-018-0065-4CARMENA, a trial comparing the efficacy of sunitinib alone to that of nephrectomy followed by sunitinib in patients with primary metastatic renal cell carcinoma who require targeted therapy has demonstrated the non-inferiority of systemic therapy alone. The data provided by this and other studies argue for a lesser role of surgery in the management of these patients. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 2, 2018 Category: Cancer & Oncology Authors: Axel Bex John Haanen Source Type: research

SLFN11: a new synthetic lethal target?
SLFN11: a new synthetic lethal target?, Published online: 29 June 2018; doi:10.1038/s41571-018-0064-5SLFN11: a new synthetic lethal target? (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - June 29, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research